详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

93| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [3]Laboratory for Bioinformatics, Fondation Jean Dausset - CEPH, Paris, France. [4]Hubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.

出处：

DOI：

ISSN：

关键词： Pan-cancer Chemotherapy Minimal residual disease DUSP1

摘要：

Chemotherapy is a commonly effective treatment for most types of cancer. However, many patients experience a relapse due to minimal residual disease (MRD) after chemotherapy. Previous studies have analyzed the changes induced by chemotherapy for specific types of cancer, but our study is the first to comprehensively analyze MRD across various types of cancer. We included both bulk and single-cell RNA sequencing datasets. We compared the expression of the entire genome and calculated scores for canonical pathway signatures and immune infiltrates before and after chemotherapy across different types of cancer. Our findings revealed that DUSP1 was the most significantly and widely enriched gene in pan-cancer MRD. DUSP1 was found to be essential for MRD formation and played a role in T cell-fibroblast communications and the cytotoxic function of CD4 + T cells. Overall, our analysis provides a comprehensive understanding of the changes caused by chemotherapy and identifies potential targets for preventing and eliminating MRD, which could lead to long-term survival benefits for patients.© 2024. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区医学

小类 | 2 区血液学 2 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 9.4 最新[2023版] 8.3 最新五年平均 11.4 出版当年[2022版] 7.3 出版当年五年平均 8.593 出版前一年[2021版] 9.4 出版后一年[2023版]

第一作者：

第一作者单位： [1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma [2]Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1 [3]Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide [4]Discovery of pan-cancer related genes via integrative network analysis. [5]Pan-Cancer Identification of Prognostic-Associated Metabolic Pathways [6]ctDNA在B细胞淋巴瘤中的研究进展 [7]Ⅲ期非小细胞肺癌精准诊疗新方向——循环肿瘤DNA与微小残留病灶 [8]Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside [9]Analysis of mutation detection of POLD1/pole in pan-cancer. [10]Pan-cancer analysis of promoter activity quantitative trait loci